

OFFICIALFAX CENTER
RECEIVED

JAN 03 1996

GROUP 1800

FAX INFORMATION
LOWE, PRICE, LEBLANC & BECKER
SUITE 300
99 CANAL CENTER PLAZA
ALEXANDRIA, VIRGINIA 22314
(703) 684-1111
FAX: (703) 684-1124185
2/6
Reeves

TO:

DATE: January 3, 1996

EXHIBIT

R 12

NAME: Examiner J. ReevesFIRM: U.S. Patent & Trademark OfficeLOCATION: Group Art Unit 1806FAX NUMBER: 305-3014NUMBER OF PAGES (Including cover): 4

FROM:

NAME: Demetra J. Mills, Esq.

RE:

Your Reference: U.S. Serial No. 08/372,676Our Reference: Docket No. 434-047**Special Instructions: The attached Supplemental Response is for consideration prior to an Examiner interview on January 25, 1996. Please forward immediately.**

Original will be sent to you:

No

X

Yes (via mail/air mail)

—

IMPORTANT

The information contained in this facsimile is intended only for the use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone, and return the original message to us at the address above via the U. S. Postal Service. Thank you.

For confirmation or assistance call (703) 518-5416 and ask for: Drew Herndon

Docket No.: 434-047

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Chatterjee et al.

Serial No. 08/372,676

Filed: January 17, 1995

Group Art Unit: 1806

Examiner: Reeves, J.

For: ANTI-IDIOTYPE MONOCLONAL ANTIBODY 1A7 AND USE FOR THE TREATMENT OF
MELANOMA AND SMALL CELL CARCINOMA

Certification of Facsimile Transmission

I hereby certify that this paper is being facsimile-
transmitted to the Patent and Trademark Office
on the date shown below.Drew R. Herndon
Type or print name of person signing certification
Signature Date 1-3-96THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D. C. 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.

- ☒ No additional fee is required.
- ☒ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☐ Also attached:

The fee has been calculated as shown below:

| | NO. OF CLAIMS | HIGHEST PREVIOUSLY PAID FOR | EXTRA CLAIMS | RATE | FEE |
|--|------------------|-----------------------------------|-----------------|----------|------|
| Total Claims | 9 | 20 | 0 | x \$11 = | 0 |
| Independent Claims | 2 | 3 | 0 | x \$39 = | 0 |
| If multiple claims newly presented, add \$125.00 | | | | | |
| Fee for extension of time | | | | | 0 |
| TOTAL FEE DUE | | | | | 0.00 |

- ☐ Please charge my Deposit Account No. 12-2237 in the amount of \$ 0.00. An additional copy of this transmittal sheet is submitted herewith.
- ☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 12-2237, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

LOWE, PRICE, LEBLANC & BECKER

Demetra J. Mills

Demetra J. Mills
Registration No. 34,50699 Canal Center Plaza, Suite 300
Alexandria, Virginia 22314
(703) 684-1111 DJM:drh
Date: January 3, 1996